

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : A23C 11/00, C12P 21/06</p>	<p>A1</p>	<p>(11) International Publication Number: WO 91/08675 (43) International Publication Date: 27 June 1991 (27.06.91)</p>
<p>(21) International Application Number: PCT/US90/07438 (22) International Filing Date: 17 December 1990 (17.12.90) (30) Priority data: 453,779 20 December 1989 (20.12.89) US (71)(72) Applicant and Inventor: SLATTERY, Charles, W. [US/US]; 11403 Golden Gate Drive, Yucaipa, CA 92399 (US). (74) Agents: DEVEZA, Robert, R. et al.; Knobbe, Martens, Olson and Bear, 620 Newport Center Drive, 16th Floor, Newport Beach, CA 92660 (US).</p>		<p>(81) Designated States: AT (European patent), AU, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LU (European patent), MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: HUMAN INFANT FORMULAS CONTAINING RECOMBINANT HUMAN ALPHA-LACTALBUMIN AND BETA-CASEIN (57) Abstract A human infant formula sufficient to meet the nutritional requirements of a human infant, comprising proteins having substantially the same amino acid sequence and biological properties as human alpha-lactalbumin and human beta-casein. The proteins may be produced from microorganisms, particularly <i>E. coli</i>. A recombinant DNA segment comprising a human milk protein encoding gene; a promoter sequence directing the transcription of the gene, where the promoter sequence is different from the promoter sequence for the gene in the human organism; and a terminator site for the human milk protein encoding gene. A microorganism containing a recombinant DNA segment comprising a human milk protein encoding gene; a promoter sequence directing the transcription of the gene; and a terminator site for the gene.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CI	Côte d'Ivoire	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

HUMAN INFANT FORMULAS CONTAINING RECOMBINANT
HUMAN ALPHA-LACTALBUMIN AND BETA-CASEIN

Background of the Invention

5 For healthy human mothers otherwise not exposed to
contaminating environmental pollutants or toxins, mother's
milk constitutes the best food for full-term, vigorous human
infants. Unfortunately, most infants are not breast fed at
all, or if breast fed, not for an adequate period of time.
10 In the United States and other developed nations, surveys
show that even during a time when the percentage of mothers
choosing to breast-feed rose from 25% to 35%, less than one-
tenth of those mothers continued to breast-feed beyond three
months (U.S. Department of Health, Education and Welfare
15 (1979), "Trends in Breast-Feeding Among American Mothers",
DHEW Publication No. (PHS) 79-1979, National Center for
Health Statistics, Hyattsville, Maryland). If second births
are considered, the percentage of breast-fed infants in all
categories is reduced even further. Consequently, a large
20 majority of American mothers still rely on bottle feeding,
either of infant formula or some other substitute for breast
milk. Presently, commercially available human infant
formula used to replace mother's milk is based primarily
upon the protein constituents of cow's milk. These infant
25 formula compositions have led to difficulties in terms of
nutrient balance, bioavailability of nutrients and
sensitivity of human infants to non-human/animal protein.
Specifically, allergic reactions to the non-human animal
protein used with these infant formulas caused a change in
30 the protein component of the commercially available formula
to soy-protein based formulas, although many infants that
are allergic to cow's milk are also allergic to soy-based
milks (Am. Acad. of Pediatrics Comm. on Nutrition,
Pediatrics, 72, 359-363 (1983)).
35 Additionally, many of the problems with the use of
cow's milk protein are associated with difficulties in

digestibility because of bovin casein content and structure (L. Hambræus, E. Forsum and B. Lonnerdal. In: "Food and Immunology", pp 116-124 (Eds. L. Hambræus, L.A. Hanson and H. McFarlane) Almquist and Wiksell (1977)).

5 This has led to the production of infant formulas which contain a greater proportion of whey protein, since it is more readily digested by human infants (M.J. Newport and M.J. Henschel, Pediatric Res., 18, 658-662 (1984)), and little or no bovine casein. However, the major protein in
10 whey of cow's milk is beta-lactoglobulin. This protein is essentially absent from human milk and has been determined to be one of the main causes of cow's milk allergy in infants. (I. Axelsson, I. Jakobsson, T. Lindberg and B. Benediktsson, Acta Paediatrica Scand., 75, 702-707
15 (1986)). The extent of the problems with allergies to formulas based on cow's milk may be appreciated from the fact that soy-based formulas now comprise a large portion of the human infant formula market in the United States.

20 Soy-protein formulas, although different in carbohydrate and protein source, are similar in composition to cow's milk-protein formulas following the American Academy of Pediatrics, Committee on Nutrition recommendations for nutrient levels in infant formulas. Differences include a slightly higher protein level and
25 slightly lower carbohydrate content. The protein source is generally soy-protein; the fat is a blend of vegetable oils; and the source of carbohydrate is usually sucrose, corn syrup solids, or a mixture of both. However, the use of soy formulas tends to raise serum alkaline phosphatase
30 and blood urea levels in infants in addition to causing the allergic and digestibility problems encountered with the use of bovine-based protein infant formulas.

Therefore, there exists a present need for a manufacturable human infant formula which comprises a
35 digestible, non-allergenic protein source. Recent research on the activity of human beta-casein has shown that the

non-phosphorylated form acts much like human casein in that it precipitates at the calcium ion levels found in mother's milk and binds to the insoluble calcium phosphate just as phosphorylated caseins do (S.M. Sood, P. Chang and C.W. Slattery, Arch. Biochem. Biophys., 264, 574-583 (1988)).

Therefore, proteins which have not been modified post-ribosomally by phosphorylation may be used along with carrageenan to replace the stabilization effects of kappa-casein in infant formula. Thus, providing human infant formulas constituted with purified non-phosphorylated human milk proteins produced by microorganisms (e.g., *E. coli* or *S. cerevisiae*) provides a unique answer in solving the inherent digestibility and allergenic problems associated with the use of non-human proteins in human infant formula compositions.

Recombinant DNA techniques may be used to clone cells producing large quantities of the necessary human proteins which may be purified and then combined with carbohydrates, lipids, minerals and sources of non-protein nitrogen to give a simulated human mother's milk formula that does not exhibit the allergenic properties associated with formulas based on cow or other foreign protein. A formula that is nutritionally adequate may be prepared by using only two human proteins: alpha-lactalbumin, which is the major protein of human whey; and beta-casein, the major protein of the casein micelle fraction of human milk. There are a variety of methods for producing these proteins. Representative procedures will be described herein.

Summary of the Invention

Thus, in accordance with one aspect of the present invention, there is provided a human infant formula of the type comprising proteins, lipids from vegetable sources, vitamins and minerals, with the improvement comprising: providing proteins in the form of proteins having substantially the same amino acid sequence and biological properties as human alpha-lactalbumin and human beta-

casein. Particularly, the proteins may be produced from microorganisms; most particularly, *E. coli*.

In accordance with another aspect of the present invention, there is provided a human infant formula comprising proteins, lipids from vegetable sources, vitamins, and minerals sufficient to meet the nutritional requirements of a human infant, in which the proteins have substantially the same amino acid sequence and biological properties as human alpha-lactalbumin and human beta-casein.

In accordance with yet another aspect of the present invention, there is provided a method to meet the nutritional requirements of human infants, comprising the steps of: providing a human infant formula comprising proteins, lipids from vegetable sources, vitamins, and minerals, in which the proteins are human alpha-lactalbumin and human beta-casein which are produced by microorganisms; and, feeding an infant the human infant formula.

In accordance with yet another aspect of the present invention, there is provided a plant, an animal or a microorganism, comprising a recombinant DNA segment comprising at least one promoted heterologous gene coding for the amino acid sequence of a protein found in human milk, the amino acid sequence preferably substantially that of human alpha-lactalbumin and/or human beta-casein.

In accordance with another aspect of the present invention, there is provided a recombinant DNA segment comprising: a human alpha-lactalbumin and/or human beta-casein encoding gene; a promoter sequence directing the transcription of the gene; and a terminator site for the gene. In a preferred embodiment, there is provided a recombinant DNA vector containing the recombinant DNA segment comprising the human alpha-lactalbumin and/or human beta-casein encoding gene.

In accordance with yet another aspect of the present invention, there is provided a method for inducing a plant,

an animal or a microorganism to produce proteins having substantially the same amino acid sequence as proteins found in human milk, comprising the steps of: inserting at least one promoted, heterologous, expressible recombinant DNA segment coding for the amino acid sequence of the protein into a recombinant DNA vector, and expressing the expressible recombinant DNA segment in a microorganism.

In accordance with still another embodiment of the present invention, there is provided a method for producing a human infant formula which contains proteins substantially comprising the amino acid sequence of human milk proteins, lipids derived from a non-human source, vitamins, minerals and other nutrients essential to meet the nutritional requirements of the human infant, comprising the steps of: inserting at least one promoted, heterologous, expressible recombinant DNA segment coding for the amino acid sequence of the human milk proteins into a vector to produce a transforming vector; transforming a microorganism by use of the transforming vector; obtaining expression of the human milk proteins by the transformed microorganism; harvesting and purifying the human milk proteins expressed by the microorganism; and formulating a human infant formula with the proteins.

Detailed Description of the Invention

25

Preparation of a cDNA Library

To produce human alpha-lactalbumin and beta-casein in microorganisms, epithelial cells from the human mammary gland must be obtained which may be treated with hormones, such as prolactin, to induce protein synthesis. Appropriate cell lines are commercially available from a variety of sources, such as the Michigan Cancer Foundation. From the prolactin treated cells, mRNA may be obtained by isolating total RNA (J.M. Chirgwin, A.E. Przybyla, R.J. MacDonald and W.J. Rutter, Biochemistry, 18, 5294-5299 (1979)), and then the poly (A)+RNA fraction (H. Avis and P. Leder, Proc.

Natl. Acad. Sci., 69, 1408-1412 (1972)). Single and double stranded cDNA are prepared from this (U. Gubler and B.J. Hoffman, Gene, 25, 263-269 (1983)), followed by ligation and transfection to construct the library, ("Current Protocols in Molecular Biology", F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith and K. Struhl, editors, John Wiley and Sons, New York (1987)) with subsequent isolation of the particular genes.

As an alternative procedure, a commercial cDNA library (HZ1037) is available from Clontech Labs, Inc. (Palo Alto, CA), prepared from human mammary tissue cells from a woman 8 months pregnant. Such a cDNA library has been used (Menon and Ham, J. Cell Biol., 107, 523a (1989); S. Menon and R.G. Ham, Nucl. Acids Res., 17, 2869 (1989)) to prepare, clone and sequence human beta-casein cDNA.

Gene Synthesis

The complete amino acid sequence is known for both alpha-lactalbumin and beta-casein:

The Amino-Acid Sequence of Human α -Lactalbumin

1 10
Lys-Gln-Phe-Thr-Lys-Cys-Glu-Leu-Ser-Gln-Leu-Leu-Lys-Asp-
25 20
Ile-Asp-Gly-Tyr-Gly-Gly-Ile-Ala-Leu-Pro-Glu-Leu-Ile-Cys-
30 30 40
Thr-Met-Phe-His-Thr-Ser-Gly-Tyr-Asp-Thr-Gln-Ala-Ile-Val-
35 50
Glu-Asn-Asp-Gln-Ser-Thr-Glu-Tyr-Gly-Leu-Phe-Gln-Ile-Ser-
40 60 70
Asn-Lys-Leu-Trp-Cys-Lys-Ser-Ser-Gln-Val-Pro-Gln-Ser-Arg-
45 80
Asn-Ile-Cys-Asp-Ile-Ser-Cys-Asp-Lys-Phe-Leu-Asn-Asp-Asn-
50 90
Ile-Thr-Asn-Asn-Ile-Met-Cys-Ala-Lys-Lys-Ile-Leu-Asp-Ile-
55 100 110
Lys-Gly-Ile-Asn-Tyr-Trp-Leu-Ala-His-Lys-Ala-Leu-Cys-Thr-
60 120
Glu-Lys-Leu-Glu-Gln-Trp-Leu-Cys-Glu-Lys-Leu
65

(J.B.C. Findlay and K. Brew. Eur. J. Biochem. 27, 65-86 (1972))

The Amino-Acid Sequence of Human β -Casein

```

5      1                               10
Arg-Glu-Thr-Ile-Glu-Ser-Leu-Ser-Ser-Ser-Glu-Glu-Ser-Ile-
10      20
Pro-Glu-Tyr-Lys-Gln-Lys-Val-Glu-Lys-Val-Lys-His-Glu-Asp-
15      30                               40
Gln-Gln-Gln-Gly-Thr-Asp-Gln-His-Gln-Asp-Lys-Ile-Tyr-Pro-
20      50
Ser-Phe-Gln-Pro-Gln-Pro-Leu-Ile-Tyr-Pro-Phe-Val-Glu-Pro-
25      60                               70
Ile-Pro-Tyr-Gly-Phe-Leu-Pro-Gln-Asn-Ile-Leu-Pro-Leu-Ala-
30      80
Gln-Pro-Ala-Val-Val-Leu-Pro-Val-Pro-Gln-Pro-Glu-Ile-Met-
35      90
Glu-Val-Pro-Lys-Ala-Lys-Asp-Thr-Val-Tyr-Thr-Lys-Gly-Arg-
40      100                               110
Val-Met-Pro-Val-Leu-Lys-Gln-Pro-Thr-Ile-Pro-Phe-Phe-Asp-
45      120
Pro-Gln-Ile-Pro-Lys-Leu-Thr-Asp-Leu-Glu-Asn-Leu-His-Leu-
50      130                               140
Pro-Leu-Pro-Leu-Leu-Gln-Pro-Ser-Met-Gln-Gln-Val-Pro-Gln-
55      150
Pro-Ile-Pro-Gln-Thr-Leu-Ala-Leu-Pro-Pro-Gln-Pro-Leu-Trp-
60      160
Ser-Val-Pro-Glu-Pro-Lys-Val-Leu-Pro-Ile-Pro-Gln-Glu-Val-
65      170                               180
Leu-Pro-Tyr-Pro-Val-Arg-Ala-Val-Pro-Val-Gln-Ala-Leu-Leu-
70      190
Leu-Asn-Gln-Glu-Leu-Leu-Leu-Asn-Pro-Pro-His-Gln-Ile-Tyr-
75      200                               210
Pro-Val-Pro-Glu-Pro-Ser-Thr-Thr-Glx-Ala-Asx-His-Pro-Ile-
80      212
Ser-Val

```

(R. Greenberg, M.L. Groves and H.J. Dower. J. Biol. Chem. 259, 5132-5138 (1984))

85 From a knowledge of the genetic code, the sequence of the nucleic acids in the genes for these proteins may be deduced and the genes themselves produced synthetically. The length of the genes, with three nucleotides per amino

acid residue, is within the capabilities of properly equipped laboratories to synthesize. In addition, the ends of the nucleotide chain comprising the gene may be designed for proper incorporation into a chosen plasmid for insertion into the microorganism and may include a start or stop codon. In the example described here, a start codon would not be needed but the sequence should end with a stop codon, such as UAA, and an unpaired sequence, complementary to the restriction endonuclease site, which is "sticky."

These genes are capable of introduction into a recipient strain by means of transformation or transfection followed by replication and amplification. Vector molecules used are plasmid DNA or DNA of temperate bacteriophages, viruses or other self-propagating DNA. Many of these methods are described in detail in the following publications:

1. Cohen, S.N.; Chang, A.C.Y.; Boyer, H.W. and Helling, R.B. (1973) Proc. Nat. Acad. Sci. USA, 70, 3240.
2. Green, P.J.; Betlach, M.D.; Boyer, H.W. and Goodman, H.N. (1974) Methods in Molecular Biology, 7, 87.
3. Tanaka, T. and Weisblum, B. (1975) J. Bacteriol., 121, 354.
4. Clarke, L. and Carbon, J. (1975) Proc. Nat. Acad. Sci. USA, 72, 4361.
5. Bolivar, F.; Rodriguez, R.L.; Green, P.J.; Betlach, M.C.; Heyneker, H.L. and Boyer, H.W. (1977) Gene, 2, 95.
6. Kozlov, J.I.; Kalinina, N.A.; Gening, L.V.; Rebentish, B.A.; Strongin, A.J.; Bogush, V.G. and Debabov, V.G. (1977) Molec. Gen. Genetics, 150, 211.

Introduction of Promoter Sequences

Different organisms, of course, recognize different promoter sequences. Therefore, various new promoter sequences appropriate for different host bacteria or yeasts may be introduced onto the genes coding for alpha-lactalbumin and/or beta-casein into a unique site in the

vect r and f r introducing the assembled DNA sequence into a variety of cloning vectors. Alternatively, the new promoter may be introduced via a particular restriction endonuclease site in the plasmid which allows for insertion of the sequence into the genome of any of a variety of appropriate host bacteria or yeast the genes calling for human alpha-lactalbumin or beta-casein. The following are a representative list of hosts and promoters:

TABLE 1

	<u>Host Bacterium or Yeast</u>	<u>Promoter</u>	<u>Reference</u>
10	<i>Corynebacterium diphtheriae</i>	Corynebacteriophage Beta toxin gene	Tweten, R.K. and Collier, R.J. <u>J. Bacteriol.</u> (1983) 156, 680-685
15		Corynebacteriophage Beta constitutive toxin gene (eg.tox-201)	Welkos, S.L. and Holmes, R.K. <u>J. Virol.</u> (1981) 37, 946-954
20		Corynebacteriophage Gamma c toxin gene	Michel, J.L., et al. <u>J. Virol.</u> (1982) 42, 510- 519
25	<i>Bacillus subtilis</i>	Sporulation gene	Ydukin, M.D., et al.
30		spo 11A	<u>J. Gen. Microbiol.</u> (1985) 131, 959-962
35		dnaE gene	Wang, L.F., et al. <u>J. Biol. Chem.</u> (1985) 260, 3368-3372
40		Aspartokinase 11 gene	Bondaryk, R.P. and Paulus, H. <u>J. Biol. Chem.</u> (1985) 260, 585- 591
45		Subtilisin E gene	Wang, S.L., et al. <u>Proc. Natl. Acad. Sci. USA</u> (1984) 81, 1184- 1188

5		rrnB operon	Steward, G.C. and Bott, K.F. <u>Nucl.</u> <u>Acids Res.</u> (1983) 11, 6289-6300
10		Alpha amylase genes (amyR2, amyE)	Yamazaki, H., et al. <u>J. Bacteriol</u> (1983) 156, 327- 337.
15		Glutamine amido- transferase gene	Makaroff, C.A., et al. <u>J. Biol.</u> <u>Chem.</u> 258, 10586- 10593
20	<i>Bacillus</i> <i>liceniformus</i>	ermD gene	Gryczan, T., et al. <u>Mol. Gen.</u> <u>Genet.</u> (1984) 194, 349-356
25		sporulation gene	Ramakrishna, N., et al. <u>Nucl.</u> <u>Acids Res.</u> (1984) 12, 1779-1790
30		PenP gene	McLaughlin, J.R. <u>Nucl. Acids Res.</u> (1982) 10, 3905- 3919
35	<i>Bacillus</i> <i>thuringiensis</i>	crystal protein gene	Wong, H.C., et al. <u>J. Biol.</u> <u>Chem.</u> (1983) 258, 1960-1967
40	<i>Pseudomonas sp.</i>	Carboxypeptidase G2 gene	Minton, N.P., et al. <u>Gene</u> (1984) 31, 31-38
45	<i>Hansenula</i> <i>polymorpha</i>	Methanol Oxidase gene	Ledeboer, A.M., et al. <u>Nucl.</u> <u>Acids Res.</u> (1985) 13, 3063-3082
50		Dihydroxyacetone Synthase gene	Janowicz, Z.A., et al. <u>Nucl.</u> <u>Acids Res.</u> (1985) 13, 1043-3062

	<i>Saccharomyces cerevisiae</i>	GAL1-GAL10 gene promoters	J hnst n, M. and Davis, R.W. <u>Mol. and Cell Biol.</u> (1984) 4, 1440- 1448
5			
10		HIS3 gene promoter	Struhl, K. <u>Proc. Natl. Acad. Sci. USA</u> (1982) 79, 7385-7389
15		HIS4 gene promoter	Donahue, T.F., et al., <u>Cell</u> (1983) 32, 89-98
20		TRP5 gene promoter	Zalkin, H. and Yanofsky, C. <u>J. Biol. Chem.</u> (1982) 257, 1491- 1500
25	<i>Saccharomyces</i>	CYC2 gene promoter	Russel, P.R. <u>Nature</u> (1983) 301, 167-169
		ADH gene promoter	Russel, P.R. <u>Nature</u> (1983) 301, 167-169
30	Any of the promoter sequences of the genes listed in Table 1 might be used advantageously for expressing human alpha-lactalbumin or beta-casein in host organisms for which they are particularly suited.		
35	Other microorganisms that may be used as host organisms for the present invention include bacteria, such as <i>Clostridium</i> sp., <i>Serratia</i> sp., <i>Enterobacter</i> sp., <i>Salmonella</i> sp., <i>Klebsiella</i> sp., <i>Rizhobium</i> sp., <i>Rhodopseudomonas</i> sp. (and other photosynthetic bacterial species), <i>Xanthamonas</i> sp., and the various methylotropic		
40	bacterial species, etc., and yeast such as <i>Candida</i> sp., <i>Saccharomyces</i> sp., <i>Hansenula</i> sp., <i>Mucor</i> sp. (and other filamentous fungi), etc..		
45	Moreover, since sufficient information is now available for the introduction and expression of foreign genes into plant and animal cells and even into mature		

plants and animals, it is possible to insert and express these human alpha-lactalbumin and beta-casein genes into these systems.

Selection of Cloning Vector

5 Vectors suitable for expression of alpha-lactalbumin or beta-casein genes have different host organisms compatibilities, primarily due to their ability or inability to adapt to the DNA replication machinery of a given host organism. Consequently, in choosing a DNA
10 vector for the expression of these genes in a given host organism, it is necessary to choose a vector capable of replication in that host organism. These DNA vectors also contain antibiotic resistance or other phenotypically selectable genes, compatible with growth and physiological
15 properties of the host organism, in order to select, propagate, amplify and maintain the human alpha-lactalbumin or beta-casein genes. A large number of suitable plasmids are known and are readily available. For any particular organism, a person of ordinary skill in the art will
20 recognize what plasmids are the most suitable, along with which plasmids provide suitable restriction endonuclease sites for recombinant DNA and promoter insertion.

Other Considerations

In addition to efficient promotion of transcription
25 for expression of alpha-lactalbumin or beta-casein genes, the economical use of the cellular transcription apparatus is favored by transcription of only those sequences required for the proper efficient translation of a messenger RNA. That is, proper transcription termination,
30 messenger RNA processing and messenger RNA translation signals must be engineered into the alpha-lactalbumin or beta-casein vectors and these signals must be compatible with the metabolic machinery of the host organism. Furthermore, it has been demonstrated that transcription
35 termination is an important factor for maintaining high copy numbers of plasmids since transcription through the

origin of replication antagonizes plasmid replication. (Adams and Hatfield (1984), J. Biol. Chem., 259, 7399-7403). Examples of these signals and their proper utilization are described below:

- 5 Transcription termination. In *E. coli*, transcription termination signals are well defined. DNA sequences containing G + C rich inverted repeats followed by 6 or more T's are known to be efficient transcription terminators. Transcription terminators in yeast are also
10 well understood. In this case, transcription termination is coupled to polyadenylation of the terminated mRNA transcript. An example of an efficient yeast transcription terminator is that of the CYC1 locus of *Saccharomyces cerevisiae* (Zaret and Sherman (1982), Cell, 28, 563-573).
15 In higher eukaryotic organisms, the mechanism of transcription termination is less well understood; however, in vitro studies (Hatfield, et al., Mol. Cell. Biol., 3, 1687-1693 (1983)) have demonstrated that the bacteriophage lambda 4S terminator contains DNA sequences that are
20 recognized by the eukaryotic RNA polymerase II, the polymerase that transcribes structural genes.

- Messenger RNA processing. Current evidence suggests that polyadenylation of prokaryotic messenger RNAs in eukaryotic organisms is important for message stability and
25 for the transport of the mRNA from the nucleus to the cytoplasm. The signal for polyadenylation, AATAAA, has been documented for many eukaryotic genes. This sequence is found in structural genes immediately downstream of the amino acid coding region.

- 30 Messenger RNA translation. In *E. coli*, it has been documented by Shine, J. and Delgarno, L. ((1975) Nature, 254, 34-38) and many other investigators that a sequence complementary to the 3'-end of the 16S ribosomal RNA is located approximately 15 nucleotides prior to the
35 translation initiation codon on the mRNA. Translation initiation is less well understood in eukaryotes; however,

as a general rule, translation appears to initiate at the first initiation codon. (Kozak (1985), Micro. Rev., 47, 1-45.)

5 In addition to the large number of general and specific considerations set forth above, it must be recognized that the mechanisms of expression vary from organism to organism. Many of these mechanisms have been elucidated at this time. Many additional mechanisms are the subject of continuing research and will be understood
10 more fully in the future. A person of ordinary skill in the art will understand, of course, which DNA sequences are needed to obtain expression of these human alpha-lactalbumin and beta-casein genes in any of the ever-expanding number of organisms; for instance, plants and
15 animals, in which expression of the DNA sequence may be desired.

The preparation and expression of the vector with the genes coding for the human proteins comprising the present invention will now be described:

20

EXAMPLE I

E. Coli Expressing Human Alpha-Lactalbumin and Beta-Casein

Preparation of the Plasmid Vector

The following procedure, with some modifications,
25 follows that used by Kang and Richardson (Y.C. Kang and T. Richardson. J. Dairy Sci. 71, 29-41 (1988)) to clone and express bovine kappa-casein in *Escherichia coli*. As a starting point, plasmid vector pKK233-2 is used. (E. Amann, J. Brosius and M. Ptashne. Gene 25, 167-178
30 (1983)). It contains a strong regulated trp-lac fusion promoter (trc promoter), the ribosome binding site of lactose operon, and an ATG start codon located eight nucleotides away from the ribosome binding site.

The start codon ATG is part of a site recognized by
35 the restriction endonuclease NcoI in which the nucleotide sequences for the two DNA strands are cleaved. This leaves

recessed 3' ends which are filled in by using the Klenow fragment of DNA polymerase I. (Y.C. Kang and T. Richardson. J. Dairy Sci., 71, 29-41 (1988)). As long as each of the four deoxynucleotide triphosphates are supplied, the reaction fills in the empty spaces to leave blunt ends on each side of the original site, and regenerates the ATG start codon required for gene expression.

In order to prevent ligation of these ends and insert the synthetic gene into the plasmid in the proper direction, a "sticky end" needs to be formed which is complementary to the one produced on the synthetic gene. The procedure (Y.C. Kang and T. Richardson. J. Dairy Sci., 71, 29-41 (1988)) is to treat the modified plasmid with the restriction endonuclease Hind III which cleaves the plasmid site to give an unpaired AGCT sequence.

In this case, because Hind III recognizes a palindromic sequence, the complementary end produced on the synthetic gene has the same AGCT sequence. The gene and the plasmid may then be mixed under the proper conditions for insertion and joined together by the action of T4 ligase (Y.C. Kang and T. Richardson. J. Dairy Sci., 71, 29-41 (1988)) to finally yield a transforming plasmid vector. The blunt end of the synthetic gene which codes for the N-terminal amino acid residue will ligate to the blunt end of the plasmid containing the ribosome binding site and the start codon while the sticky end following the stop codon will ligate to the sticky end of the Hind III site in the plasmid.

30 Transformation and Cloning

The ligation mixture is then used to transform competent cells of *E. coli* JM105. (J. Messing. Methods Enzymol., 101, 20-78 (1983)). The cells are then grown on plates in media containing LB-ampicillin. Since the PKK233-2 plasmid has a gene coding for resistance to ampicillin, only those cells which have incorporated the

plasmid will survive. The surviving colonies are then transferred to LB-ampicillin broth for growth and checked for the expression of the desired protein, either alpha-lactalbumin or beta-casein, using antibodies. Those colonies that express the desired proteins are then grown and the expected proteins are isolated by any of a number of conventional methods such as harvesting the cells and isolating the protein from cell extract; or by collecting secreted protein in growth medium. (R. Hawkes. Anal. Biochem., 123, 143-146 (1982)). A large percentage of the protein produced by the *E. coli* cells prepared in this manner is either alpha-lactalbumin or beta-casein.

EXAMPLE II

Human Milk Protein Production in Yeast

In a manner similar to that described in Example I for *E. coli*, plasmids are constructed, for introduction into *S. cerevisiae*, which have sections for autonomous extrachromosomal replication, ampicillin resistance and binding to the spindle apparatus during mitosis as well as a section containing a portion of a bacterial plasmid that directs expression of foreign protein ("The Molecular Biology of the Yeast *Saccharomyces*: Life Cycle and Inheritance" (1981) and "The Molecular Biology of the Yeast *Saccharomyces*: Metabolism and Gene Expression" (1982), J.N. Strathern, E.W. Jones and J.R. Broach, editors, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.). Proteins are not only expressed but are also believed to be secreted (K.M. Zsebo, H.-S. Lu, J.C. Fieschko, L. Goldstein, J. David, K. Duker, S.V. Suggs, P.-A. Lai and G.A. Bitter, J. Biol. Chem. 261, 5858-5865 (1986)).

Protein Purification

The production of large amounts of single proteins by cells simplifies the purification procedures. A two-step procedure separates the alpha-lactalbumin from cytosol proteins by ion exchange chromatography with DEAE-cellulose and gel filtration with Sephadex G-75. (J.G. Shewale, S.K.

Sinha and K. Brew. J. Biol. Chem., 259, 4947-4956 (1984)). Prot in is assayed by its ability to promote lactose synthesis with galactosyl transferase. (K. Br w, H.M. Steinman and R.L. Hill. J. Biol. Chem., 248, 4739-4742 (1973)). Similarly, beta-casein is separated by isoelectric precipitation, ion-exchange chromatography and gel filtration. (S.M. Sood, P. Chang and C.W. Slattery. Arch Biochem. Biophys. 242, 355-364 (1985)). Purified proteins may be freeze-dried for convenience of storage and use in formulation of infant food.

Preparation of Infant Formula

Once the genetically engineered human alpha-lactalbumin and beta-casein have been separated and purified, they are combined in a human infant formula. The formulation of infant formula based on bovine alpha-lactalbumin and casein has been defined. (V.S. Packard. "Human Milk and Infant Formula" pp. 147-154. Academic Press (1982)). It is suggested that the whey proteins and caseins be in a ratio of 60:40 or 0.9 weight percent alpha-lactalbumin to 0.6 weight percent casein for a total of 1.5 g protein/100 ml of milk. However, computer optimization of this ratio for the human proteins, to obtain amounts of each amino acid corresponding to the amounts actually found in human milk requires a ratio of 40:50 or 0.67 weight percent alpha-lactalbumin to 0.83 weight percent beta-casein (a total of 1.5 g protein/100 ml of milk) to reach known levels of all the essential amino acids. Supplementary amino acids, such as L-methionine used in soy-based formulas, are not needed.

Calcium is preferably of a chemical form that is biologically compatible and commercially available, such as from SIGMA Chemical Co., and should be preferably present to a minimum of 50 mg/100 kcal. Minimum phosphorus level is 25 mg/100 kcal. Minimum and maximum amounts of sodium, potassium, and chloride must also be observed. These levels are met within the ranges 6-17, 14-34, and 11-29

milliequivalents (mEq), respectively, in a formula providing 670 kcal/liter. One milliequivalent is equal to the atomic weight (in milligrams) of the element divided by valence. Osmolarity - in moles of solute/liter - should not exceed 400 mOsm.

Caloric density of infant formulas of 670 kcal/liter appears nearly optimal for normal full-term infants. The formulation should provide a calcium-phosphorus ratio preferably of not less than 1.1:1.0 nor more than 2:1. Most preferably, the ratio is near 1.5:1, at least through most of the first year of life. By one year of age, the appropriate ratio is more nearly 1:1.

Infant formulas can vary in composition, but within fairly narrow and quite precise limits. In general, as a complete substitute for human milk, formula is preferably comprised of protein at 7-16% of calories, with a preferable ratio of alpha-lactalbumin to beta-casein ranging from about 70:30 to about 30:70, fat at 30-54% of calories, linoleic acid at 2-3% of calories, and the remaining calories from carbohydrate sources. The fat component of the formula preferably comprised of various vegetable fats. Because many contaminants or pollutants of food are soluble in fat, specially refined vegetable fats and oils provide better control of formula contents. To prevent conversion of *cis* to *trans* fatty acids, and loss thereby of essential fatty acids, low- (or ultra-high) temperature treatment is preferably used throughout processing.

A representative list of ingredients follows:

Water
Lactose (Corn Syrup or Sucrose could be used)
Human Alpha-Lactalbumin
Human Beta-Casein
Coconut Oil
Soybean Oil
Modified Corn Starch

Mono- and Diglycerides

Soy Lecithin

Carrageenan

Vitamin Sources

5 Vitamin A Palmitate

Vitamin D3

Alphatocopheryl Acetate (Vitamin E)

Phytonadione (Vitamin K)

Ascorbic Acid (Vitamin C)

10 Thiamine Chloride Hydrochloride (Vitamin B1)

Riboflavin

Cyanocobalamin (Vitamin B12)

Niacinamide

Calcium Pantothenate

15 Pyridoxine Hydrochloride (Vitamin B6)

Biotin

Folic Acid

Choline Chloride

Mineral Sources

20 Calcium Phosphate, Tribasic

Cupric Sulfate

Ferrous Sulfate

Magnesium Chloride

Potassium Chloride

25 Potassium Citrate

Potassium Iodide

Zinc Sulfate

The amounts of each of the ingredients listed are adjusted to keep each nutritional component within the maximum and minimum guidelines recommended by the FDA (V.S. Packard. "Human Milk and Infant Formula" pp. 147-154. Academic Press (1982)) and by the American Academy of Pediatrics, (Am. Acad. of Pediatrics Comm. on Nutrition, Pediatrics, 72, 359-363 (1983)), as disclosed below (modified from American Academy of Pediatrics, Committee on Nutrition: Commentary on Breast-Feeding and Infant Formulas, including

proposed standards for formulas. Pediatrics, 57, 278 (1976):

Nutrient Levels of Infant Formulas (per 100 kcal)

(adapted from: Anderson, S.A., H.I. Chinn, and K.D. Fisher. A background paper on infant formulas, Life Sciences Research Office, Federation of American Societies for Experimental Biology, Bethesda, Maryland, (1980))

	<u>Nutrient</u>	<u>Minimum</u>	<u>Maximum</u>
10	Protein (g)	1.8	4.5
	Fat		
	(g)	3.3	6.0
	(% cal)	30.0	54.0
15	Essential fatty acids (linoleate)		
	(%cal)	3.0	--
	(mg)	300.0	--
	Vitamins		
20	A (IU)	250.0 (75 µg)	750.0 (225 µg)
		(Retinol equivalents)	
	D (IU)	40.0	100.0
	K (µg)	4.0	--
	E (IU)	0.3 (with 0.7	--
25		IU/g linoleic acid)	
	C (ascorbic acid)		
	(mg)	8.0	--
	B ₁ (thiamine) (µg)	40.0	--
30	B ₂ (riboflavin) (µg)	60.0	--
	B ₆ (pyridoxine) (µg)	35.0 (with 15 µg	--
		of protein in formula)	
	B ₁₂ (µg)	0.15	--
35	Niacin		
	(µg)	250.0	--
	(µg equiv)	--	--
	Folic acid (µg)	4.0	--
	Pantothenic acid (µg)	300.0	--
40	Biotin (µg)	1.5	--
	Choline (mg)	7.0	--
	Inositol (mg)	--	--
	Minerals		
	Calcium (mg)	40.0	--
45	Phosphorus (mg)	25.0	--
	(Calcium to phosphorus ratio must be no less		
	than 1.1 to 1.0 nor more than 2.0 to 1.0)		
	Magnesium (mg)	6.0	--
	Iron (mg)	0.15	--
50	Iodine (µg)	5.0	--
	Zinc (mg)	0.5	--
	Copper (µg)	60.0	--

	Manganese (μ g)	5.0	--
	Sodium (mg)	20.0 (mEq)	60.0 (17 mEq)
	Potassium (mg)	80.0 (14 mEq)	200.0 (34 mEq)
	Chloride (mg)	55.0 (11 mEq)	150.0 (29 mEq)
5	(Milliequivalents for 670 kcal/liter of formula)		

Carbohydrate sources include lactose (or milk and whey products that contain lactose), sucrose, corn syrup solids(a source of glucose), and starch.

Appropriate thickening agents, emulsifiers, antioxidants, and compounds for adjusting pH may be used. In the United States, conditions of use of additives in infant formula are regulated under the Code of Federal Regulations (CFR), Title 21, Section 172.620 and Section 180.

Vitamin additives for use in infant formulas are approved by the Food and Agricultural Organization (FAO). Processing requirements, availability, and/or stability in the specific food system will dictate which form(s) will serve best.

The FAO also approves mineral sources for infant formula. Suitability of any given mineral additive depends on composition and moisture level of the food product. Furthermore, each food imposes its own requirements for flavor and/or textural stability. Oxidative rancidity is an ever-present problem in iron and/or copper-fortified foods containing unsaturated fats. Gelation is a potential problem in concentrated liquid infant formulas. Reduced iron or electrolytic iron, which serve well in dry foods, will settle out as a sediment in liquid formula. FAO also recognizes the need for acids and bases for making pH adjustments; however, these must be accounted for in determining total content of any given mineral.

Certain mineral compounds, for instance, calcium and phosphorus, are required in fairly large amounts in infant formula. Other mineral elements are required only in trace amounts. Thus, trace minerals in ingredients of infant

formula must be considered, along with th s that may be added in water supplies used to reconstitute various dry ingredients. Water supplies may or may not be treated for this purpose, depending upon the overall quality. Water
5 quality should be monitored, however, along with the trace mineral content of finished formula.

When trace minerals are added to formula, sulfate salts are commonly used. Acceptable levels of sulfate ions, however, have not been specified (Anderson, et al.
10 (1980)). Because of the potential to cause methemoglobinemia, nitrate salts are usually not added to formula. A trace amount may occur in formula made up of vegetable products. Nitrates also occur and are occasionally found at high levels in some water supplies.
15 Copper is another potentially toxic component of water. However, any biologically acceptable salt composition is contemplated for use in the present invention.

Minerals commonly added to formulas include calcium, phosphorus, magnesium, iron, copper, iodine, zinc, potassium, sodium, manganese, and chlorine (as chloride).
20 Conventional infant formula compositions require the addition of bovine or soy protein sources which may have a significant amount of minerals carried along with the protein component. The presence of these minerals decreases the accuracy of determining the mineral
25 components of the manufactured infant formula. Conventional methodologies, including electrodialysis, ion exchange and ultrafiltration, are commonly used to separate the proteins from the minerals and other contaminants associated with them. Use of the recombinant DNA-derived
30 human proteins of the present invention in human infant formula reduce the amount protein purification necessary, thus providing a more accurate determination of mineral content and reduced expenditures for protein processing.

35 Formulations for Premature Infants

For preterm or low-weight infants (under 2500 g), formulas are usually modified, with the evaluation of protein and mineral levels. Lactose level may preferably be lowered by one-third to one-half regular amounts, with
5 the difference made up with more readily absorbable carbohydrate source such as corn syrup solids. Fat, calcium, and phosphorus must be available in readily utilizable form.

Caloric density is preferably raised to 800-1000
10 kcal/liter; with approximately 11% of the calories from protein and 50% from fat. In general, corn and soy oil appear reasonably well absorbed by premature infants.

While particular embodiments of the invention have been described in detail, it will be apparent to those
15 skilled in the art that the disclosed embodiments may be modified. Therefore, the foregoing description is to be considered exemplary rather than limiting, and the true scope of the invention is that defined in the following claims.

IN THE CLAIMS:

1. In a human infant formula of the type comprising proteins, lipids from vegetable sources, vitamins and minerals, the improvement comprising:
 - 5 providing said proteins in the form of proteins having substantially the same amino acid sequence and biological properties as human alpha-lactalbumin and human beta-casein.
2. The formula of Claim 1, wherein said proteins are
10 produced from a microorganism.
3. The formula of Claim 2, wherein said microorganism is *E. coli*.
4. A human infant formula comprising proteins, lipids from vegetable sources, vitamins and minerals
15 sufficient to meet the nutritional requirements of a human infant, wherein said proteins have substantially the same amino acid sequence and biological properties as human alpha-lactalbumin and human beta-casein.
5. The human infant formula of claim 4, wherein said
20 proteins are produced from microorganisms.
6. A method to meet the nutritional requirements of human infants, comprising the steps of:
 - 25 providing a human infant formula comprising proteins, lipids from vegetable sources, vitamins and minerals, wherein said proteins are human alpha-lactalbumin and human beta-casein, said proteins produced by microorganisms; and
 - feeding said infant said human infant formula.
7. A host organism including a recombinant DNA
30 segment comprising at least one promoted heterologous gene coding for the amino acid sequence of a protein found in human milk.
8. The host organism of Claim 7, wherein said amino
35 acid sequence is substantially that of human alpha-lactalbumin.

9. The host organism of Claim 7, wherein said amino acid sequence is substantially that of human beta-casein.

10. The host organism of Claim 7, wherein said recombinant DNA segment comprises a promoter sequence
5 directing the transcription of said heterologous gene.

11. The host organism of Claim 7, wherein said recombinant DNA segment comprises ribosome binding sites and a terminator for said heterologous gene.

12. The host organism of Claim 7, wherein said host
10 organism is a microorganism.

13. The host organism of Claim 7, wherein said host organism is an animal.

14. The host organism of Claim 7, wherein said host organism is a plant.

15 15. A recombinant DNA segment comprising:
a human alpha-lactalbumin encoding gene;
a promoter sequence directing the transcription
of said gene, wherein said promoter sequence is
different from the promoter sequence for said gene in
20 the human organism; and
a terminator site for said gene.

16. A recombinant DNA vector containing the DNA segment of Claim 15.

17. A method for inducing a host organism to produce
25 proteins having substantially the same amino acid sequence as proteins found in human milk, comprising the steps of:

inserting at least one promoted, heterologous,
expressible recombinant DNA segment coding for said
amino acid sequence of said protein into a recombinant
30 DNA vector; and
expressing said segment in a microorganism.

18. The method of Claim 17, wherein said host organism is a microorganism.

19. The method of Claim 17, wherein said host
35 organism is a plant.

20. The method of Claim 17, wherein said host organism is an animal.

21. A method for producing a human infant formula; said formula comprising proteins substantially comprising the amino acid sequence of human milk proteins, lipids derived from a non-human source, vitamins, minerals and other nutrients essential to meet the nutritional requirements of a human infant, comprising the steps of:

10 inserting at least one promoted, heterologous, expressible recombinant DNA segment coding for said amino acid sequence of said human milk proteins into a vector to produce a transforming vector;

transforming a microorganism by said transforming vector;

15 obtaining expression of said protein by said transformed microorganism;

harvesting and purifying said protein expressed by said microorganism; and

20 formulating said human infant formula with said proteins.

22. The method of Claim 21, wherein said obtaining step comprises obtaining secretion of said protein.

23. A recombinant DNA segment comprising:


25 a human beta-casein encoding gene;
a promoter sequence directing the transcription of said gene, wherein said promoter sequence is different from the promoter sequence for said gene in the human organism; and

a terminator site for said gene.

30 24. A recombinant DNA vector containing the DNA segment of Claim 23.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US90/07438

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ²		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC(5): A23C 11/00; C12P 21/06		
U.S. CL.: 426/580; 435/69.1		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System ¹	Classification Symbols	
U.S.	426/580,585,801; 435/69.1	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ³		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ^{1*}		
Category ²	Citation of Document, ^{1*} with indication, where appropriate, of the relevant passages ^{2*}	Relevant to Claim No. ^{1*}
A	US, A, 4,544,633 (GIL ET AL.) 01 October 1985, See the abstract.	1,4
Y	US, A, 4,753,926 (LUCAS ET AL.) 28 June 1988, See Column 6, lines 40-51.	1,4,6
Y	US, A, 4,961,938 (HAYENGA ET AL.) 09 October 1990, See the abstract.	2,3,5, 6,21,22
Y	Brock, T.D., Smith, D.W., and Madigan, M.T. "Biology of Microorganisms", published 1984, by Prentice-Hall, Inc. (Englewood Cliffs, New Jersey), see pages 379-400, especially page 380, Figure 12.1.	1-6,21 22
Y	Findlay, J.B.C. and Brew, K. "The Complete Amino-Acid Sequence of Human -Lactalbumin", <u>European Journal of Biochemistry</u> , 27, pages 65-84 (1972), See abstract.	1-6,21, 22
<p>[*] Special categories of cited documents: ^{1*}</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"G" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ¹	Date of Mailing of this International Search Report ¹	
13 MARCH 1991	22 APR 1991	
International Searching Authority ¹	Signature of Authorized Officer ^{1*}	
ISA/US	 LESLIE WOOD	

Form PCT/ISA/210 (second sheet) (May 1988)

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y	Greenberg, R., Groves, M.L. and Dower, H.J. "Human β -Casein Amino Acid Sequence and Identification of Phosphorylation Sites", <u>The Journal of Biological Chemistry</u> , Vol. 259, No. 8, pages 5132-5138, 1984, See the abstract.	1-6,21, 22
Y	Packard, V.S. "Human Milk and Infant Formula", published 1982, by Academic Press (New York), see pages 147-154, especially page 150.	1-6,21, 22

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____ because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____ because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers _____ because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 8.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

- I. Claims 1-6, 21 and 22 drawn to infant formula, feeding the formula and a method for producing formula. Class 426, subclass 2 and 580.
- II. Claims 7-16, 23 and 24 drawn to a host organism with DNA encoding milk proteins and DNA vectors. Class 435, subclass 69.1.

(See attached Sheet)

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers those claims of the international application for which fees were paid, specifically claims:

3. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims: it is covered by claim numbers: **1-6, 21 and 22**

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority invites payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
☐ No protest accompanied the payment of additional search fees.

PCT/US90/07438
EXTRA SHEET #1

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING (CONT.)

Claims 17-20 drawn to a method of inducing expression of milk proteins from host organism. Class 435, subclass 69.1.

Group I relates to a first product, process of making the product and the use of the product. Group II relates to a second product and process. Group III relates to a third process.

